Study on Racial Encounters and Discrimination Experienced by South Asians Executive Summary Background 1. A survey on “Study on Racial Encounters and Discrimination Experienced by South Asians” was commissioned by the Equal Opportunities Commission (EOC) to the Centre for Civil Society and Governance, The University of Hong Kong, and the Policy 21 Limited. Interviews
- A |
J |K |
U |V |
Doi:10.1016/s0140-6736(03)13920-7e-mail submissions to [email protected] Mortality reduction by breast-cancer screening yield accorded with the trial results: one This article, together with other reports Julius Center for Health Sciences and Primary Care, Utrecht Medical Center, HP D 01.335, PB 85500, 3508 GA Utrecht, Netherlands(e-mail: [email protected]) Otto SJ, Fracheboud J, Looman CWN, et al.
mammography screening in Dutchmunicipalities and effect on breast-cancer change in (disease-free) life expectancy.
mortality: a systematic review. Lancet 2003; 361: 1411–17.
National Evaluation Team for Breast Cancer neither is the mortality reduction, which Screening. Landelijke evaluatie vanbevolkingsonderzoek naar borstkanker in 8-year period of screening, 3·13 million Nederlands, vol IX [National evaluation of population screening for screening].
Visser D, Coebergh JWW, Schouten LJ, van Dijk JAAM (eds). Incidence of cancer in the Netherlands 1997. Utrecht: Vereniging women since 1980 was rather striking.
Frisell J, Nordenskjöld B, Rutqvist LE.
Long-term effects of mammographyscreening: updated overview of the Swedish randomised trials. Lancet 2002; 359: 909–19.
Black WC, Haggstrom DA, Welch H.
All cause mortality in randomized trials of cancer screening. J Natl Cancer Inst 2002;
Sir—Suzie Otto and colleagues1conclude that changes in use ofadjuvant systemic therapy are an introduction of population-basedmammography screening in the Netherlands. They assumed that theproportion of node-positive patients Incidence of and mortality from breast cancer in women aged 50–75 years in the Before 1989, only first hospital-admissions of breast cancer as the primary diagnosis were available.
THE LANCET • Vol 362 • July 19, 2003 • www.thelancet.com For personal use. Only reproduce with permission from The Lancet.
Nordic Cochrane Centre, Rigshospitalet Dept 7112, Blegdamsvej 9, DK-2100 Copenhagen,Denmark Adri C Voogd, Jan Willem W Coebergh municipalities and effect on breast-cancer University, PO Box 616, 6200 MD Maastricht, mortality: a systematic review. Lancet 2003; 361: 1411–17.
Registry, Comprehensive Cancer Centre South, La Vecchia C. Cancer mortality in Europe,1990–1994, and an overview of trends from 1955 to 1994. Eur J Cancer 1999; 35:
Levi F, Lucchini F, Negri E, La Vecchia C.
municipalities and effect on breast-cancer The fall in breast cancer mortality in
Europe. Eur J Cancer 2001; 37: 1409–12.
mortality: a systematic review. Lancet 2003;
handbooks of cancer prevention. Volume 7: breast cancer screening. Lyon: IARC Press, cancer in southeast Netherlands since 1984: when tumours were receptor-positive.
a population-based study. Acta Oncol 1994;
Frisell J, Nordenskjöld B, Rutqvist LE.
screening: updated overview of the Swedish randomised trials. Lancet 2002; 359:
Louwman WJ, Klokman WJ, Coebergh JW.
Excess mortality from breast cancer 20 years normal. Br J Cancer 2001; 84: 700–03.
guidelines for adjuvant systemic treatment of breast cancer at hospital level [in Dutch].
Ned Tijdschr Geneeskd 2000; 144: 1572–74.
for screening between 1991 and 1996.
endocrine treatment is difficult. A later those aged 50–69 years (16·3% vs THE LANCET • Vol 362 • July 19, 2003 • www.thelancet.com For personal use. Only reproduce with permission from The Lancet.
Media contacts PRESS RELEASE EMBARGOED until Thursday, 2 May 2013, 12:00 (CEST) GENETIC AND CLINICAL FACTORS BEST FOR PREDICTING LATE RECURRENCE IN OESTROGEN RECEPTOR POSITIVE BREAST CANCER Presentation at the 5th IMPAKT Breast Cancer Conference Lugano-CH, Brussels-BE, 2 May 2013 -- A new analysis has provided a comprehensive comparison of scores designed to predict which